Moreover, significant amounts of clinical study have demonstrated the loss of CYLD expression in a variety of malignant tumors, such as, hepatocellular carcinoma [16, 17], melanoma [18], basal cell carcinoma [19], breast cancer [20], glioblastoma [21], and cholesteatoma [22]. This evidence concerns the gene CYLD and hepatocellular carcinoma.